Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. | Semantic Scholar
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies | Cell Death & Disease
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes | MedPage Today
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
PDF) Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication | Cell Death & Disease
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
Diffuse Large B-Cell Lymphoma | NEJM
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma | Acta Pharmacologica Sinica
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
:%0A%0AAbexinostat%20+%20Ibrutinib%20for%20Lymphoma.png?md=1 "Abexinostat + Ibrutinib for Lymphoma Clinical Trial 2024 | Power")
Abexinostat + Ibrutinib for Lymphoma Clinical Trial 2024 | Power
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
